Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

One in eight American adults have used a GLP-1 agonist. This class of drugs are prescribed for weight loss, to treat diabetes, and to reduce the risk of heart attack and stroke in adults with heart ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

Not too long ago I would have said I was one of the least likely people to be tempted by GLP-1s like Wegovy or Zepbound. My weight has always been average. I have no medical conditions, and more than ...

LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...